Literature DB >> 33082016

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.

Nadia R P W Hutten1, Natasha L Mason1, Patrick C Dolder1, Eef L Theunissen1, Friederike Holze2, Matthias E Liechti2, Amanda Feilding3, Johannes G Ramaekers1, Kim P C Kuypers1.   

Abstract

There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Attention; Healthy; LSD; Microdose; Mood; Psychedelic experience

Year:  2020        PMID: 33082016     DOI: 10.1016/j.euroneuro.2020.10.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

1.  Natural language signatures of psilocybin microdosing.

Authors:  Camila Sanz; Federico Cavanna; Stephanie Muller; Laura de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar; Facundo Carrillo; Adolfo M García; Carla Pallavicini; Enzo Tagliazucchi
Journal:  Psychopharmacology (Berl)       Date:  2022-06-09       Impact factor: 4.415

Review 2.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

3.  Dosing Psychedelics and MDMA.

Authors:  Matthias E Liechti; Friederike Holze
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 4.  Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

Authors:  Albert Garcia-Romeu; Sean Darcy; Hillary Jackson; Toni White; Paul Rosenberg
Journal:  Curr Top Behav Neurosci       Date:  2022

5.  Safety pharmacology of acute LSD administration in healthy subjects.

Authors:  Friederike Holze; Toya V Caluori; Patrick Vizeli; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2021-09-13       Impact factor: 4.415

6.  Self-blinding citizen science to explore psychedelic microdosing.

Authors:  Balázs Szigeti; Laura Kartner; Allan Blemings; Fernando Rosas; Amanda Feilding; David J Nutt; Robin L Carhart-Harris; David Erritzoe
Journal:  Elife       Date:  2021-03-02       Impact factor: 8.140

7.  Asking questions of psychedelic microdosing.

Authors:  Lindsay P Cameron
Journal:  Elife       Date:  2021-03-02       Impact factor: 8.140

8.  MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.

Authors:  Robin J Murphy; Rachael L Sumner; William Evans; David Menkes; Ingo Lambrecht; Rhys Ponton; Frederick Sundram; Nicholas Hoeh; Sanya Ram; Lisa Reynolds; Suresh Muthukumaraswamy
Journal:  Trials       Date:  2021-04-23       Impact factor: 2.279

9.  Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.

Authors:  Josephine Marschall; George Fejer; Pascal Lempe; Luisa Prochazkova; Martin Kuchar; Katerina Hajkova; Michiel van Elk
Journal:  J Psychopharmacol       Date:  2021-12-17       Impact factor: 4.153

Review 10.  Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.

Authors:  Maria Bălăeţ
Journal:  Front Neurosci       Date:  2022-03-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.